StreetAlpha.app
Home › Stocks › CNTB

Connect Biopharma Holdings Ltd (CNTB)

$0.57
▼ −11.43%
LAST CLOSE · NOV 17

Connect Biopharma is a San Diego company developing rademikibart, an antibody in trials for asthma and COPD. It last closed at $0.57 on Nov 17, down 11.43% on the day. The average 12-month price target from 6 analysts is $5.33 (+836.5% from the last close), with a high of $7.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).

AI Auto Pilots
Is CNTB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.7M
+382.0% vs a year ago
Net income
−$67.9M
−1849.7% margin
EPS (diluted)
−$1.14
Free cash flow
−$55.3M
−1504.2% margin
Valuation
Market cap
$36.7M
64.5M shares
P/E
–
No P/E while losing money
Price to sales
10.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.5M
At Sep 30
Shareholder equity
$12.1M
Shares outstanding
64.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $26.0M$26.0MFY2024FY2025: $64K$64KFY2025

From CNTB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on CNTB in the past 90 days
Average 12-month target
$5.33
▲ 836.5% upside

Based on 6 analysts who set a price target on CNTB in the past 90 days. The average target is $5.33, with a high of $7.00 and a low of $4.00, compared with the last close of $0.57.

Low $4.00Avg $5.33High $7.00
Blue marker: last close $0.57
Highest target$7.00
Average target$5.33
Lowest target$4.00
Latest rating changes
Canaccord GenuityMaintained
Nov 17Buy$6
Piper SandlerTarget lowered
Nov 17Buy$7 → $5
Leerink PartnersAssumed coverage
Oct 12Buy$4
BTIGTarget lowered
Sep 30Buy$10 → $5
OppenheimerTarget lowered
Sep 22Buy$8 → $5
DateFirmActionRatingPrice target
Nov 17Canaccord GenuityMaintainedBuy$6
Nov 17Piper SandlerTarget loweredBuy$7 → $5
Oct 12Leerink PartnersAssumed coverageBuy$4
Sep 30BTIGTarget loweredBuy$10 → $5
Sep 22OppenheimerTarget loweredBuy$8 → $5
Loading…

Technical Analysis

CNTB · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 32% below its 20 day and 74% below its 50 day average. It is 267% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the 52 week low at $0.55, and the nearest resistance the Pivot at $0.59.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 14.2%/day
Key levels
$3.8252 week high+570.2%
$2.09200 day average+266.7%
$1.63100 day average+186.0%
$0.9950 day average+73.7%
$0.87Swing high (Oct 30)+52.6%
$0.7520 day average+31.6%
$0.62Pivot R1+8.8%
$0.59Pivot+3.5%
$0.57Last close
$0.5552 week low−3.5%
$0.53Pivot S1−7.0%
Indicators
RSI (14)23.96Oversold below 30Oversold
MACD-0.11Below its signal lineBearish
Stochastic13.6Near the bottom of its rangeOversold
ADX (14)16.5No clear trend
Williams %R-94.0Oversold below −80, overbought above −20Oversold
CCI (20)-195.9Oversold below −100, overbought above 100Oversold
Rate of change−26.4%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 14.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CNTB

What happened before

See how CNTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CNTB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CNTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CNTB in the last 90 days.

Loading…

See today’s whale options flow across the market →

CNTB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲39 buying vs 24 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6557+14.0%
In funds' top 1000–
Held by funds23.3%21.6%+1.6 pts
New / increased17 / 2225 / 15−2.5%
Reduced / sold out15 / 99 / 10+26.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CNTB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNTB is in one of them and how their past CNTB trades turned out.

CNTB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CNTB in an article yet. Here's the latest on the wider market.

About Connect Biopharma Holdings

Connect Biopharma is a biopharmaceutical company based in San Diego, California. It is developing rademikibart, an antibody designed to block a receptor involved in airway inflammation. The drug is in clinical trials for sudden worsening episodes of asthma and chronic obstructive pulmonary disease (COPD), which are lung conditions that make breathing difficult. The company's target market is patients with these diseases and the hospitals that treat them, although the drug is not yet approved for sale.

Headquarters
San Diego, CA